TRCT
HCAT icon

Tower Research Capital (TRC)’s Health Catalyst HCAT Stock Holding History

Tower Research Capital (TRC)’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.5K Buy
38,958
+28,231
+263% +$40.8K ﹤0.01% 2383
2026
Q1 		$13.6K Buy
10,727
+6,182
+136% +$11.6K ﹤0.01% 3731
2025
Q4 		$10.9K Buy
4,545
+469
+12% +$1.28K ﹤0.01% 3691
2025
Q3 		$11.6K Sell
4,076
-3,057
-43% -$10.5K ﹤0.01% 3869
2025
Q2 		$26.9K Buy
7,133
+3,577
+101% +$14.1K ﹤0.01% 3487
2025
Q1 		$16.1K Buy
3,556
+2,020
+132% +$10.7K ﹤0.01% 3182
2024
Q4 		$10.9K Sell
1,536
-16,018
-91% -$128K ﹤0.01% 3773
2024
Q3 		$143K Buy
17,554
+6,228
+55% +$45K ﹤0.01% 1941
2024
Q2 		$72.4K Buy
11,326
+10,525
+1,314% +$67.6K ﹤0.01% 2824
2024
Q1 		$6.03K Sell
801
-11,217
-93% -$102K ﹤0.01% 4445
2023
Q4 		$111K Buy
12,018
+8,900
+285% +$72.7K ﹤0.01% 2572
2023
Q3 		$31.6K Buy
3,118
+1,942
+165% +$23.2K ﹤0.01% 2978
2023
Q2 		$14.7K Sell
1,176
-188
-14% -$2.24K ﹤0.01% 3678
2023
Q1 		$16K Buy
1,364
+159
+13% +$2.03K ﹤0.01% 3697
2022
Q4 		$13K Sell
1,205
-4,635
-79% -$44.7K ﹤0.01% 3608
2022
Q3 		$57K Sell
5,840
-15,892
-73% -$210K ﹤0.01% 3038
2022
Q2 		$315K Buy
21,732
+20,335
+1,456% +$347K 0.01% 1446
2022
Q1 		$36K Buy
1,397
+212
+18% +$6.01K ﹤0.01% 2981
2021
Q4 		$47K Sell
1,185
-2,543
-68% -$116K ﹤0.01% 2808
2021
Q3 		$187K Buy
3,728
+2,746
+280% +$150K ﹤0.01% 1883
2021
Q2 		$55K Sell
982
-2,748
-74% -$146K ﹤0.01% 2947
2021
Q1 		$174K Buy
3,730
+1,992
+115% +$96.5K ﹤0.01% 2135
2020
Q4 		$76K Sell
1,738
-28,339
-94% -$1.05M ﹤0.01% 2625
2020
Q3 		$1.1M Buy
30,077
+25,682
+584% +$872K 0.01% 899
2020
Q2 		$128K Buy
+4,395
New +$121K 0.01% 2229
2020
Q1 		– Sell
-659
Closed -$23K – 3390
2019
Q4 		$23K Buy
659
+464
+238% +$15.4K ﹤0.01% 1829
2019
Q3 		$7K Buy
+195
New +$7.67K ﹤0.01% 3140

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $239M AUM
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC)'s HCAT Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Health Catalyst (HCAT) stake by 263% in Q2 2026, buying an estimated $40.8K and bringing the position to 38,958 shares worth $77.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2383.

Tower Research Capital (TRC) first reported a position in HCAT in Q3 2019 and has held it in 27 quarters since. The position peaked at $1.1M in Q3 2020. 126 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

  • Tower Research Capital (TRC) held 38,958 shares of Health Catalyst worth $77.5K as of Q2 2026.
  • Tower Research Capital (TRC) bought 28,231 Health Catalyst shares in Q2 2026, an estimated $40.8K.
  • Health Catalyst made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2383 holding.
  • Tower Research Capital (TRC) first reported a position in Health Catalyst in Q3 2019 and has held it in 27 quarters since.
  • Tower Research Capital (TRC)'s Health Catalyst position peaked at $1.1M in Q3 2020.
  • 126 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.